Invesco Ltd. Increases Stock Position in OraSure Technologies, Inc. $OSUR

Invesco Ltd. raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 11.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 141,951 shares of the medical instruments supplier’s stock after purchasing an additional 14,425 shares during the period. Invesco Ltd.’s holdings in OraSure Technologies were worth $478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Spire Wealth Management purchased a new position in OraSure Technologies during the first quarter valued at $54,000. Assenagon Asset Management S.A. lifted its position in OraSure Technologies by 9.4% during the first quarter. Assenagon Asset Management S.A. now owns 164,260 shares of the medical instruments supplier’s stock valued at $554,000 after buying an additional 14,132 shares during the period. Northern Trust Corp lifted its position in OraSure Technologies by 6.7% during the fourth quarter. Northern Trust Corp now owns 693,887 shares of the medical instruments supplier’s stock valued at $2,505,000 after buying an additional 43,628 shares during the period. Two Sigma Investments LP purchased a new position in OraSure Technologies during the fourth quarter valued at $552,000. Finally, Deutsche Bank AG raised its position in shares of OraSure Technologies by 68.5% in the 4th quarter. Deutsche Bank AG now owns 72,672 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 29,545 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

OSUR has been the subject of several recent analyst reports. Wall Street Zen raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 17th. Evercore ISI reaffirmed an “in-line” rating and issued a $3.00 price target on shares of OraSure Technologies in a research report on Monday, May 19th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.00.

OraSure Technologies Stock Performance

NASDAQ OSUR opened at $3.23 on Friday. OraSure Technologies, Inc. has a one year low of $2.36 and a one year high of $4.60. The stock has a 50-day moving average of $3.09 and a 200 day moving average of $3.08. The company has a market capitalization of $236.24 million, a price-to-earnings ratio of -4.82 and a beta of 0.44.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.